Dr. Mikhael Blagosklonny was born in Russia. He attended the First Pavlov State Medical University of St. Petersburg where he earned both his M.D. in Internal Medicine and his PhD in Cardiology and Experimental Medicine. He eventually emigrated to the United States and in 2002 started work at New York Medical Hospital in Valhalla, New York, as a Professor of Medicine. He has also worked as a Chair at the Cleveland Clinic Foundation as well as a Professor of Biochemistry at Case Western University. In 2009 he took a position as a Professor of Oncology at Roswell Park Cancer Insitute, which is based in Buffalo, New York.
Dr. Blagosklonny performs cancer research and is particularly interested in how TOR signaling plays a role in cancer and aging. In his research into the cancer drug Rapamycin he has discovered that it can possibly give people an extension on life by slowing or perhaps even stopping the aging process. This has informed his research into Rapamycin and how it should play a role in longevity research.
Dr. Blagosklonny edits a number of medical journals. He is an editor-in-chief for Oncotarget, Aging, and Cell Cycle. He also is a member of the editorial board for Cell Death & Differentiation, as well as an associate editor of the medical journal Cancer Biology & Therapy. Dr. Mikhael Blagosklonny has 270 papers published in peer-reviewed medical journals and has well over 25,000 citations by other researchers.
In addition to being a professor at Roswell Park Cancer Institute Dr. Blagosklonny is also the Senior Vice President of Basic Science Chair, Cell Stress Biology and holds The Garman Family Chair in Cell Stress Biology. In his position at the institute he is responsible for working in the Cell Stress Biology program and its research into areas such as DNA damage and repair and photodynamic therapy. He is tasked with assisting the President and Chief Executive Officer of the institute in developing and implementing new scientific programs as well as fostering strategic relationships with other academic institutions across the United States. Visit his LinkedIn profile.